Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV-Reference-Cited by-同舟云学术

Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV

Published:2018-11-23 Issue:4 Volume:124 Page:456-465
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Niu Wan‐jie¹,Sun Tao²,Liu Li²,Liu Xiao‐qian²,Zhang Ren‐fang²,Yin Lin²,Wang Jiang‐rong²,Jia Xiao‐fang²,Lu Hong‐Zhou²,Zhong Ming‐kang¹,Jiao Zheng¹,Zhang Li‐jun²

Affiliation:

1. Department of Pharmacy Huashan, Hospital Fudan University Shanghai China

2. Shanghai Public Health Clinical Center ShanghaiChina

Funder

13th Five-Year National Major New Drug Development

Key Issues of Shanghai Municipal Commission of Health and Family Planning

the Weak Discipline Construction Project from Shanghai Municipal Commission of Health and Family Planning

2016 Key Clinical Program of Clinical Pharmacy of Shanghai Municipal Commission of Health and Family Planning

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcpt.13154

Reference44 articles.

1. ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease

2. World Health Organization (WHO).Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach: 2010 Revision.2010[updated 2010]http://www.who.int/hiv/pub/arv/adult2010/en/. Accessed May 23 2018.

3. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review

4. Assessment of Lopinavir Pharmacokinetics With Respect to Developmental Changes in Infants and the Impact on Weight Band–Based Dosing

5. Metabolism and Disposition of the HIV-1 Protease Inhibitor Lopinavir (ABT-378) Given in Combination with Ritonavir in Rats, Dogs, and Humans

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods;Drug Metabolism Reviews;2024-03-06

2. Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study;BMC Pharmacology and Toxicology;2023-09-27

3. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis;Drug Metabolism and Pharmacokinetics;2022-12

4. Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals;International Journal of Peptide Research and Therapeutics;2022-11-25

5. Effects of cimetidine on ciclosporin population pharmacokinetics and initial dose optimization in aplastic anemia patients;European Journal of Pharmaceutical Sciences;2022-07